Inactivation of p110δ in macrophages inhibits mammary tumour growth and reduces the recruitment of macrophages in mice, and PI3Kδ inhibitors may be considered in clinical trials for the treatment of breast cancer in the future (Goulielmaki et al. 2018). Here, PIK3CD is linked to breast carcinoma.